NASDAQ: CNTBConnect Biopharma Holdings Ltd Stock
$1.26-0.15 (-10.64%)
Updated Oct 7, 2024
CNTB Price
$1.26
Fair Value Price
$0.27
Market Cap
$69.48M
52 Week Low
$0.68
52 Week High
$2.84
P/E
-3.1x
P/B
0.63x
P/S
3.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.12M
Earnings
-$22.82M
Gross Margin
100%
Operating Margin
-94.02%
Profit Margin
-94.6%
Debt to Equity
0.09
Operating Cash Flow
-$28M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNTB Overview
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company developing immune modulators for the treatment of serious autoimmune diseases and inflammation. Its lead candidates are CBP-201, a treatment for inflammatory allergic diseases (atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps), CBP-307, for the treatment of autoimmune-related inflammation diseases, CBP-174 to treat chronic itch associated with skin inflammation, and CBP-233 to treat T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CNTB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTB ($1.26) is overvalued by 361.47% relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CNTB ($1.26) is not significantly undervalued (361.47%) relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CNTB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNTB due diligence checks available for Premium users.
Be the first to know about important CNTB news, forecast changes, insider trades & much more!
CNTB News
Valuation
CNTB fair value
Fair Value of CNTB stock based on Discounted Cash Flow (DCF)
Price
$1.26
Fair Value
$0.27
Overvalued by
361.47%
CNTB ($1.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNTB ($1.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNTB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNTB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.1x
Industry
-111.33x
Market
26.63x
CNTB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
5.95x
CNTB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTB's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CNTB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CNTB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$120.6M
Liabilities
$10.1M
Debt to equity
0.09
CNTB's short-term assets ($115.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTB's short-term assets ($115.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CNTB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTB vs Biotech Stocks
Connect Biopharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.